ALK and non-small cell lung carcinoma: A phase III trial (CROWN [33]) showed that the PFS of patients with stage IV ALK-p NSCLC and PS 0–1 is significantly longer with lorlatinib monotherapy than with crizotinib in the overall patient population and a subgroup of patients with CNS metastases (HR 0.28, 95% CI: 0.19–0.41).